Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5953746 | 0.85 | HTR5A (0.33) | — | |
| SCHEMBL5953749 | 0.85 | HTR5A (0.33) | — | |
| SCHEMBL5953142 | 0.81 | CHRM2 (0.30) | CHRM2CHRM1CHRM3 | |
| SCHEMBL5953140 | 0.81 | CHRM2 (0.30) | CHRM2CHRM1CHRM3 | |
| SCHEMBL15467154 | 0.75 | CARM1 (0.46) | — | |
| SCHEMBL15473844 | 0.75 | HRH3 (0.33) | — | |
| SCHEMBL14155722 | 0.74 | CYP2D6 (0.42) | CHRM3 | |
| SCHEMBL7699465 | 0.73 | CYP2D6 (0.39) | CHRM2CHRM1CHRM3 | |
| SCHEMBL7699463 | 0.73 | CYP2D6 (0.39) | CHRM2CHRM1CHRM3 | |
| SCHEMBL18600363 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1532109-B1 | PYRROLIDINE DERIVATIVES AS OXYTOCIN ANTAGONISTS | MERCK SERONO SA (CH) | 2009-09-09 | — | — | EP | disclosed |
| US-7115754-B2 | Pyrrolidine derivatives as oxytocin antagonists | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2006-10-03 | — | — | US | disclosed |
| US-20060004020-A1 | Pyrrolidine derivatives as oxytocin antagonists | MERCK SERONO SA (CH) | 2006-01-05 | — | — | US | disclosed |
| EP-1532109-A1 | PYRROLIDINE DERIVATIVES AS OXYTOCIN ANTAGONISTS | Applied Research Systems ARS Holding N.V. (AN) | 2005-05-25 | — | — | EP | disclosed |
| WO-2004005249-A1 | PYRROLIDINE DERIVATIVES AS OXYTOCIN ANTAGONISTS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004020-A1 | Pyrrolidine derivatives as oxytocin antagonists | OXTR, PRLHR, AVPR1A | CHRM2 1029/4885CHRM1 233/4885CHRM3 1146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.